January 23, 2023
JNJ.com: 2 Big Ideas to Help Lower the Risk of Maternal-Fetal Complications in BIPOC Women
Women from historically underrepresented communities have a higher risk of pregnancy complications. So Johnson & Johnson Innovation challenged researchers to propose potential solutions that aim to address this troubling healthcare disparity. These awardees just might be the game changers.
January 18, 2023
NX Prenatal Announces Addition of Dr. Robert Bonebrake to Strategic Advisory Board
NX Prenatal Inc. today announced that Robert G. Bonebrake, MD, FACOG has joined its Strategic Advisory Board. Dr. Bonebrake is a partner with Perinatal Associates at The Methodist Perinatal Center at Nebraska Methodist Women’s Hospital. He is also a Clinical Associate Professor in the Department of Obstetrics and Gynecology at the University of Nebraska Medical Center, and currently serves as the President of the Medical Staff for Nebraska Methodist Health system and is the past Chair of the Department of Maternal and Child for Methodist Health System. Dr. Bonebrake also serves as the Chair of the State of Nebraska Maternal Mortality Committee and the Co- Medical Director of the Nebraska Perinatal Quality Improvement Collaborative. He has numerous publications and has many invited presentations, with special emphasis on antenatal diagnosis of complications of pregnancy and delivery.
January 5, 2023
NX Prenatal Announces Breakthrough Findings for the Detection of Placenta Accreta
NX Prenatal Inc. and its collaborators have published the results of a new clinical study demonstrating the utility of its proprietary exosome-based liquid biopsy platform for the detection of biomarkers that have the potential to identify pregnant patients with Placenta Accreta Spectrum (PAS). There are no current blood tests for this condition which is a significant contributor to maternal morbidity and mortality. Pregnant moms that have had prior C-Sections or other gynecologic surgical procedures are at heightened risk for PAS. The current imaging techniques are estimated to capture only one-third to one-half of cases (primarily high grade). The findings were published in Scientific Reports.
November 17, 2022
World Prematurity Day 2022: Extracellular Vesicles as Predictors of Premature Birth
In the search for biomarkers of premature birth, EVs are showing promise. EVs are released by all cells, including those of the placenta, allowing for peripheral sampling of placental biomarkers. EVs also protect their cargo which is delivered to target cells, providing a source of circulating biomarkers which would otherwise be degraded. These advantages of EVs as biomarker sources has driven a surge of research into EV biomarkers for preterm birth. Leading the way in this space is NX Prenatal, a company developing diagnostic tests to predict preterm birth and other pregnancy complications based on EVs.
November 1, 2022
NX Prenatal Named as an Awardee in Maternal-Fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity
NX Prenatal Inc. has been selected as an awardee of the Maternal-fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity. Launched by Johnson & Johnson Innovation in collaboration with the Office of the Chief Medical Officer of The Johnson & Johnson Family of Companies (OCMO) Health of Women team, together with The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), the QuickFire Challenge award will include grant funding and mentorship from experts to help catalyze innovations directed toward the prevention of adverse pregnancy outcomes.
April 1, 2021
NX Prenatal Announces Initiation of a Clinical Study for the Detection of Placenta Accreta
NX Prenatal Inc. announced today that it is a sponsor and collaborator for an upcoming clinical study whereby its NeXosome® liquid biopsy platform will be key in the detection of biomarkers that can identify pregnant patients with Placenta Accreta Spectrum (PAS). Pregnant moms that have had prior C-sections, or IVF-assisted conception, or prior D&C procedures are known to be in elevated risk categories for PAS, but there is no current blood test that can help identify which of those moms may experience this life-threatening condition.
January 27, 2021
NX Prenatal Expands Leading Patent Position in Exosome-Based Liquid Biopsy Tests in Maternal- Fetal Medicine
NX Prenatal Inc. today announced that it has achieved new patent issuances in both the United States and Europe for its exosome-based liquid biopsy tests for the early identification of pregnant mothers at elevated risk for spontaneous preterm birth. NX Prenatal controls worldwide rights to a portfolio of more than three dozen pending and issued patents that feature the earliest and most comprehensive claims related to the utilization of exosomes for the detection and management of adverse pregnancy outcomes.